Literature DB >> 23372536

Patient Evaluation and OA Study Design: OARSI/Biomarker Qualification.

Virginia Byers Kraus1.   

Abstract

Entities:  

Keywords:  Anesthesiology; FDA; Imaging / Radiology; Medicine & Public Health; Orthopedics; Rheumatology; Sports Medicine; Surgical Orthopedics; biomarkers; drug development tools; osteoarthritis; qualification

Year:  2011        PMID： 23372536      PMCID： PMC3295932          DOI： 10.1007/s11420-011-9234-z

Source DB:  PubMed          Journal:  HSS J        ISSN： 1556-3316


× No keyword cloud information.
  4 in total

1.  Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs.

Authors:  J A Wagner; S A Williams; C J Webster
Journal:  Clin Pharmacol Ther       Date:  2007-01       Impact factor: 6.875

2.  Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis.

Authors:  V B Kraus; B Burnett; J Coindreau; S Cottrell; D Eyre; M Gendreau; J Gardiner; P Garnero; J Hardin; Y Henrotin; D Heinegård; A Ko; L S Lohmander; G Matthews; J Menetski; R Moskowitz; S Persiani; A R Poole; J-C Rousseau; M Todman
Journal:  Osteoarthritis Cartilage       Date:  2011-03-23       Impact factor: 6.576

3.  Summary and recommendations of the OARSI FDA osteoarthritis Assessment of Structural Change Working Group.

Authors:  P G Conaghan; D J Hunter; J F Maillefert; W M Reichmann; E Losina
Journal:  Osteoarthritis Cartilage       Date:  2011-03-23       Impact factor: 6.576

4.  The Food and Drug Administration's Osteoporosis Guidance Document: past, present, and future.

Authors:  Eric G Colman
Journal:  J Bone Miner Res       Date:  2003-06       Impact factor: 6.741
  4 in total
  2 in total

1.  Effect of chondroitin sulfate on soluble biomarkers of osteoarthritis: a method to analyze and interpret the results from an open-label trial in unilateral knee osteoarthritis patients.

Authors:  Ingrid Möller; Myriam Gharbi; Helena Martinez Serrano; Marta Herrero Barbero; Josep Verges Milano; Yves Henrotin
Journal:  BMC Musculoskelet Disord       Date:  2016-10-06       Impact factor: 2.362

Review 2.  Soluble biomarkers development in osteoarthritis: from discovery to personalized medicine.

Authors:  Yves Henrotin; Christelle Sanchez; Anne Cornet; Joachim Van de Put; Pierre Douette; Myriam Gharbi
Journal:  Biomarkers       Date:  2015       Impact factor: 2.658
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.